## Table 8 |
||||

DDI definitions in corpus |
||||

DDI relationship |
C1 |
C2 |
C3** |
C4** |

IN VIVO STUDY |
||||

DDI |
Yes |
Yes |
The PK parameter with the highest priority* must satisfy p-value <0.05 and FC > 1.50 or FC < 0.67 | Significant, obviously, markedly, greatly, pronouncedly and etc. |

Ambiguous DDI (ADDI) |
The PK parameter with the highest priority* in the conditions of p-value <0.05 but 0.67 < FC < 1.50; or FC >1.50 or FC <0.67, but p-value > 0.05. | Modestly, moderately, probably, may, might, and etc. | ||

Non-DDI (NDDI) |
The PK parameter with the highest priority*are in the condition of p-value > 0.05 and 0.67 < FC < 1.50 | Minor significance, slightly, little or negligible effect, doesn’t interact etc. | ||

IN VITRO STUDY |
||||

DDI |
Yes |
Yes |
(0< Ki < 10 or 0< EC50 < 10 microM, and p-value <0.05) | Significant, obviously, markedly, greatly, pronouncedly and etc. |

DEI |
||||

Ambiguous DDI (ADDI) |
(10 < Ki < 100 or 10 < EC50 < 100 microM, and p-value <0.05 or vice versa) | Modestly, moderately, probably, may, might, and etc. | ||

Ambiguous DEI (ADEI) |
||||

Non-DDI (NDDI) |
(Ki > 100 microM or EC50 > 100 microM, and p-value >0.05) | Minor significance, slightly, little or negligible effect, doesn’t interact etc. | ||

Non-DEI (NDEI) |

Note:

C1: At least one drug or enzyme name has to be contained in the sentence.

C2: Need to label the drug name if it is not from the same sentence.

C3: PK-parameter and value dependent.

C4: Significance statement.

*Priority issue: When C3 and C4 occur and conflict, C3 dominates the sentence.**For
the priority of PK parameters: AUC > CL > t_{1/2} > C_{max;}; the priority of *in vitro* PK parameters: Ki>IC50.

Wu * et al.*

Wu * et al.* *BMC Bioinformatics* 2013 **14**:35 doi:10.1186/1471-2105-14-35